Valiant Organics Limited · NSE:VALIANTORG
Valiant Organics — Q4 FY24 Earnings Presentation
28 slides from Valiant Organics's earnings presentation, Jun 17, 2024
Slide 1: Letter to stock exchanges: Investor Presentation
June 17, 2024 To, To, Listing/Compliance Department Listing/Compliance Department BSE LTD National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, “Exchange Plaza”, Plot No. C/1, Mumbai- 400 001. G Block Bandra-Kurla Complex, Bandra (E), Mumbai- 400 051 . SCRIP CODE - 540145
Slide 2: Investor Presentation | June 2024
Investor Presentation | June 2024 1
Slide 3: Snapshot
SNAPSHOT One of the largest chlorophenol One of the leading manufacturer of derivatives manufacturer globally Benzene derivatives products One of the largest domestic PNA One of the few commercial players in manufacturer Ortho Anisidine and Para Anisidine Diversified client base across Amongst 1st f
Slide 4: Company Overview
eeee Valiant 01 9000 COMPANY OVERVIEW
Slide 5: Company Overview
Company Overview Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered out of Mumbai, India. The company is focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries, including agrochemicals, pharmac
Slide 6: Board of Directors
Board of Directors Shri Mahek M. Chheda Shri Navin C. Shah Shri Sathiababu K. Kallada (Chief Financial Officer & (Chairman & Independent (Managing Director) Executive Director) Director) Shri Nemin Savadia Shri Siddharth Shah Shri Parimal Hasmukhlal Desai (Executive Director) (Executive Director) (N
Slide 7: Key Milestones
Key Milestones Emerged as a major supplier of Listed on the NSE in Chlorophenols in India and the July. Completed Expanded product range global markets. Acquired Amarjyot Phase 1 of the PAP to include Chlorophenols, Chemicals, a large specialised factory and Achieved ramp up for usage in intermediat
Slide 8: Manufacturing Footprint
Manufacturing Footprint CHLORINATION – SARIGAM HYDROGENATION & METHOXYLATION- • Capacity: 18,000 MTPA JHAGADIA UNIT 1 • Products: PCP, OCP, 2,4 DCP, 2,6 DCP, • Capacity: 27,000 MTPA 2,4,6 TCP • Products: ONA/OA, PNA/PA, IPPCA, CONVERSION PRODUCTS AMMONOLYSIS - VAPI HYDROGENATION – JHAGADIA UNIT 2 •
Slide 9: Key Strengths
Key Strengths Domain expertise and broad Plant locations are process understanding in a Wide supply chain strategically located near variety of chemistries. The provides the continuous ports to provide a executive team is made up of availability of adequate competitive advantage, first-generation te
Slide 10: Capex Projects
Capex Projects Product Project Status Remarks Ongoing Projects • Currently, entirely imported in India Ortho Amino Phenol (OAP) Expected to commence • Part of the production will be utilized as forward integration for one of company's existing products • Trial run successful however, further improve
Slide 11: Business Overview
seco Valiant Organics Limited 9000 BUSINESS OVERVIEW
Slide 12: Chemistries And Product Basket
Chemistries And Product Basket FY24 Revenue Share Hydrogenation Ammonolysis 41% Key Products: Industries Served: Key Products: • Ortho Anisidine Industries Served: • Dyes • Para Nitro Aniline • Para Anisidine • Dyes • Pigments • Ortho Chloro Para Nitro Aniline • IPPCA • Pigments • Pharmaceutical • M
Slide 13: Chlorination
Chlorination Any reaction in which chlorine or chlorine compounds are introduced into a molecule to obtain the desired outcome Revenues (INR Mn)* is known as chlorination. 3,000 2,765 • Valiant is the only domestic player and also a global leader in Chlorophenol products with ~25% global market 2,13
Slide 14: Ammonolysis
Ammonolysis Ammonolysis is a high-pressure chemical reaction done in an auto clave where ammonia is used as a reactant. Revenues (INR Mn)* • Valiant developed Ammonolysis capabilities as a result of its two acquisitions. i.e. Abhilasha Tex Chem Pvt. Ltd. 3,500 2,917 in 2017 & Amarjyot Chemicals Ltd.
Slide 15: Hydrogenation
Hydrogenation Hydrogenation is a chemical reaction between molecular hydrogen (H2) and another compound or element, usually in the presence of a catalyst. Revenues (INR Mn)* • The company has manufacturing facilities in Jhagadia for Hydrogenation. The first unit (also named as Unit 1) 5,000 4,331 ha
Slide 16: Other Processes
Other Processes Acetylation Revenues (INR Mn)* Acetylation is a chemical reaction which introduces an acetyl functional group into a chemical compound. 855 • The acetylation procedure is carried out at the company’s Ahmedabad facility which has a capacity of 1,800 900 800 MTPA 700 600 530 564 • The
Slide 17: Industry Overview
seco Valiant Organics Limited 9000 INDUSTRY OVERVIEW
Slide 18: Industry Overview
Industry Overview • Expansive Product Portfolio: India's chemical landscape is vast, boasting over 80,000 commercial products, offering a diverse array of solutions to global demands. Global Chemical Market (USD Bn) • Global Manufacturing Powerhouse: Positioned as the 6th largest manufacturer of che
Slide 19: Advantage India: Key Growth Factors
Key Growth Factors GROWING POLICY INCREASING ADVANTAGE INDIA OPPORTUNITIES DEMAND SUPPORT INVESTMENT • Rise in demand from end-users • Supply disruption in China has • The government plans to Industries such as food processing, caused the global end-user • FDI inflows in the chemicals sector impleme
Slide 20: Financial Overview
seco Valiant Organics Limited 9000 FINANCIAL OVERVIEW
Slide 21: Historical Consolidated Income Statement
Historical Consolidated Income Statement Particulars (INR Mn) FY21 FY22 FY23 FY24 Revenue from Operations 7,548 11,533 10,518 7,231 Total Expenses 5,496 9,484 8,875 6,849 EBITDA 2,052 2,049 1,643 382 EBITDA Margins (%) 27.19% 17.77% 15.62% 5.28% Other Income 59 74 80 93 Depreciation 212 296 292 349
Slide 22: Consolidated Balance Sheet
Consolidated Balance Sheet Particulars (INR Mn) FY22 FY23 FY24 Particulars (INR Mn) FY22 FY23 FY24 EQUITY 6,489 7,401 7,293 Non-Current Assets 6,652 7,682 8,352 a) Equity Share Capital 272 272 276 a) Property, Plant and Equipment 5,303 6,565 6,297 b) Other Equity 5,856 6,616 7,017 c) Right-Of-Use As
Slide 23: Historical Standalone Income Statement
Historical Standalone Income Statement Particulars (INR Mn) FY21 FY22 FY23 FY24 Revenue from Operations 5,742 9,484 9,116 6,772 Total Expenses 4,170 7,811 7,817 6,376 EBITDA 1,572 1,673 1,299 396 EBITDA Margins (%) 27.38% 17.64% 14.25% 5.85% Other Income 169 33 29 29 Depreciation 186 273 276 340 Fin
Slide 24: Standalone Balance Sheet
Standalone Balance Sheet Particulars (INR Mn) FY22 FY23 FY24 Particulars (INR Mn) FY22 FY23 FY24 EQUITY 6,031 6,661 6,649 Non-Current Assets 6,787 7,424 7,818 a) Equity Share Capital 272 272 276 a) Property, Plant and Equipment 5,085 6,092 6,297 b) Other Equity 5,755 6,385 6,373 b) Right-Of-Use Asse
Slide 25: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 14,000 80.00% 1,400 1,309 1,279 2,052 2,049 11,533 2,100 70.00% 12,000 1,026 10,518 1,643 1,100 1,800 60.00% 10,000 7,548 1,500 50.00% 800 8,000 7,231 1,200 40.00% 500 6
Slide 26: Capital Market Information
Capital Market Information Share Price up to 31st March, 2024 50% 30% 10% -10% -30% -50% -70% Apr-23 May-23 Jun-23 Jul-23 Aug-23 Sep-23 Oct-23 Nov-23 Dec-23 Jan-24 Feb-24 Mar-24 Valiant Organics Sensex Price Data (As on 31st March, 2024) INR Shareholding pattern (As on 31st March, 2024) FII; 1.14% D
Slide 27: Disclaimer
Disclaimer Valiant Organics Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all event
Slide 28: Thank You
eeee Valiant 01 9000 THANK YOU